Zanzalintinib and Pembrolizumab in First-Line Maintenance for Metastatic Squamous Non-Small Cell Lung Cancer (NSCLC)

Authors
Category Primary study
Registry of TrialsClinicalTrials.gov
Year 2026
The primary purpose of the study is to evaluate the effectiveness of zanzalintinib in combination with pembrolizumab as first-line maintenance therapy in participants with metastatic squamous NSCLC.
Epistemonikos ID: 275e996e00db4623f272531a354dfc7ebe99b3fe
First added on: Sep 30, 2026